报价延迟最少15分钟:2025/07/21 11:59 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.1364 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-6.37/-0.00
|
|
企业价值
1.24M
|
| 资产负债 |
|
每股账面净值
0.60
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/21 11:59 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms, Isomyosamine and Supera-CBD. Isomyosamine is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailtyand sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B. The company has one reportable segment focused on Isomyosamine. |
